Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026 - … Biogen to Acquire Apellis, Enhancing the Company’s Growth … Growth Outlook and Accelerating Expansion into Nephrology Biogen to Acquire Apellis, Enhancing the Company’s Growth … two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, …
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026 - … Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose … points; +15.1 vs. -11.1, p<0.0001). “Over the past decade, Biogen has continued to listen, learn, and innovate to help … Executive Vice President and Head of Development at Biogen. “With more than 10 years of clinical data on …
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
March 28, 2026 - … Biogen Announces Second Positive Phase 2 Litifilimab Trial in … Showing a Significant Reduction in Skin Disease Activity Biogen Announces Second Positive Phase 2 Litifilimab Trial in … CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from …
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
March 20, 2026 - … Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that new real‑world findings from an … and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and …
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
March 19, 2026 - … Biogen to Present New Late-Breaking Litifilimab Phase 2 … at 2026 American Academy of Dermatology Annual Meeting Biogen to Present New Late-Breaking Litifilimab Phase 2 … CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming …
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026 - … Biogen Presents Additional Salanersen Data Showing New Motor … in Children with SMA Previously Treated with Gene Therapy Biogen Presents Additional Salanersen Data Showing New Motor … to deliver high efficacy in SMA with once-yearly dosing Biogen also debuted the design of the Phase 3 salanersen …
Biogen to Participate in the Stifel 2026 Virtual CNS Forum
March 10, 2026 - … Biogen to Participate in the Stifel 2026 Virtual CNS Forum Biogen to Participate in the Stifel 2026 Virtual CNS Forum … March 10, 2026 News Release General Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Diana … Biogen to Participate in the Stifel 2026 Virtual CNS Forum …
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
March 5, 2026 - … Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences Biogen to Share New SMA Data at Muscular Dystrophy … CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and … Biogen to Share New SMA Data at Muscular Dystrophy …
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
March 4, 2026 - … by harnessing the body’s potential with RNA medicine, and Biogen Inc . (NASDAQ: BIIB), today announced the publication … Dawson, M.D., Head of Therapeutics Development Unit at Biogen. “For more than 10 years Biogen has been advancing cutting-edge research to address …
Biogen to Participate in the Leerink Global Healthcare Conference 2026
March 3, 2026 - … Biogen to Participate in the Leerink Global Healthcare Conference 2026 Biogen to Participate in the Leerink Global Healthcare … March 3, 2026 News Release General Cambridge, MA , - - Biogen Inc. (Nasdaq: BIIB) announced today that Uptal … Biogen to Participate in the Leerink Global Healthcare …
